3 years of historical data (2022–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Apogee Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Market Cap | $4.2B | $2.5B | $1.4B | — |
| Enterprise Value | $4.0B | $2.4B | $1.3B | — |
| P/E Ratio → | -21.21 | — | — | — |
| P/S Ratio | — | — | — | — |
| P/B Ratio | 5.39 | 3.49 | 3.73 | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -33.2% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Profit Margin | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ROE | -33.2% | -33.2% | -32.2% | -28.0% |
| ROA | -31.5% | -31.5% | -30.3% | -26.2% |
| ROIC | -38.3% | -38.3% | -55.0% | — |
| ROCE | -39.2% | -39.2% | -35.6% | -21.6% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $142M exceeds total debt of $12M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | — |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | -0.18 | -0.31 | -1.07 |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | — | — | — | -3.36 |
Net cash position: cash ($142M) exceeds total debt ($12M)
Short-term solvency ratios and asset-utilisation metrics
Apogee Therapeutics, Inc.'s current ratio of 18.55x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 15.24x to 18.55x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Current Ratio | 18.55 | 18.55 | 19.38 | 15.24 |
| Quick Ratio | 18.55 | 18.55 | 19.38 | 15.24 |
| Cash Ratio | 18.23 | 18.23 | 19.24 | 15.22 |
| Asset Turnover | — | — | — | — |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Apogee Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $55M | $51M | $51M |
Compare APGE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| APGEYou | $4B | -21.2 | — | — | — | — | -33.2% | -38.3% | — |
| ARGX | $47B | 60.0 | — | — | 89.6% | -1.0% | 17.4% | -0.5% | — |
| CANF | $14B | -4.4 | — | — | 100.0% | -1206.2% | -134.9% | -448.3% | — |
| AKTX | $13B | -0.0 | — | — | — | — | -179.9% | -172.5% | — |
| ABVX | $10B | -36.7 | — | — | 100.0% | -1602.9% | -149.0% | — | — |
| RAPT | $8B | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
| KYMR | $7B | -24.8 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| PTGX | $6B | -44.9 | — | 99.9 | — | — | -20.2% | -21.8% | — |
| IMVT | $6B | -10.2 | — | — | — | — | -62.5% | — | — |
| TGTX | $5B | 200.6 | 114.4 | — | 88.3% | 12.7% | 12.2% | 13.3% | 6.0 |
| KNSA | $3B | 59.3 | 41.0 | 133.6 | — | 11.4% | 23.6% | 17.1% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 3 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how APGE stacks up against sector leader argenx SE.
Start ComparisonApogee Therapeutics, Inc.'s current P/E ratio is -21.2x. This places it at the 50th percentile of its historical range.
Apogee Therapeutics, Inc.'s return on equity (ROE) is -33.2%. The historical average is -31.1%.
Based on historical data, Apogee Therapeutics, Inc. is trading at a P/E of -21.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.